Acquiring Company
Hikma Pharmaceuticals
Acquired Company
Xellia
Ohio
DenmarkManufacturingBiotechnologyHealth CarePharmaceuticalManufacturingDescription
Hikma, a London-based generics maker, has agreed to acquire parts of Xellia's U.S. assets, including the manufacturing facility in Cleveland. The acquisition will bolster Hikma's U.S. injectable manufacturing capabilities and portfolio, adding significant scale to its operations and complex technologies. This strategic move is part of Hikma's commitment to enhancing its productivity, expanding into the CDMO business, and strengthening its position in the market.
Who to call at Hikma Pharmaceuticals, and when
When Hikma Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Hikma Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Hikma Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Hikma Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Hikma Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Xellia?
Xellia was acquired by Hikma Pharmaceuticals, based in Ohio. The deal was reported on June 20, 2024. Hikma Pharmaceuticals is a leading player in the U.S. generic drug market. Hikma Pharmaceuticals is privately held and operates in Manufacturing.
When did Hikma Pharmaceuticals acquire Xellia?
Hikma Pharmaceuticals's acquisition of Xellia was reported on June 20, 2024. Hikma, a London-based generics maker, has agreed to acquire parts of Xellia's U.S. assets, including the manufacturing facility in Cleveland. The acquisition will bolster Hikma's U.S. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Xellia do?
Xellia is a Danish drugmaker with assets in the U.S. Its manufacturing facility in Cleveland features end-to-end capabilities to develop, manufacture, pack, and distribute lyophilized vials and aseptically filled ready-to-use IV bag products. It is privately held, operating in Manufacturing, and is based in Denmark.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.